ecancer

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative...

Overall survival in older patients with glioblastoma

Cancer Survivorship

Benign lesions that mimic breast cancer

Treatment of late stage adenocarcinoma

Diagnosis and staging of lung adenocarcinoma

Non-randomised clinical trial aims to describe safety and efficacy of available, anticancer drugs

Examining cancer plans to develop cancer control programmes

Comparison of coplanar and non-coplanar beam plans as treatment for prostate SBRT

Health related quality of life as a potential predictor for mortality

Sentinel node biopsy: Dyes for identification

Large B cell non-hodgkin’s lymphoma: Optimising therapy for elderly patients

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-p...

Clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing o...

Breast cancer incidence in post-menopausal women: Long-term influence of oestrogen plus progesti...

Low dose exemestane usage in breast cancer

AACR 2009: Chemokine inhibitors to prevent tumour growth

Sentinel lymph node mapping and biopsy for early stage oral cavity cancer

Evolving medical treatment in advanced/recurrent endometrial cancer

HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive disease free survival

Breast and cervical cancer rates influenced by HRT, not contraceptive pill

ECCO14: Oncology nursing and the importance of patient education.

Nurturing healthy coping strategies in cancer patients

Why choose medical oncology? Trainee perspective

Optimal use of tyrosine kinase inhibitors as a treatment for Philadelphia chromosome-positive ac...

Comment: Critical quality attributes of biosimilars

Clinical trials of low-dose aspirin combined with low-dose rivaroxaban

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

Ponatinib and blinatumomab for patients with Philadelphia chromosome-positive ALL

Management of HER2 positive metastatic breast cancer treatment algorithm

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients

The role of lymph nodes in stage 3 lung cancer

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy pts

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression

ASCO 2022: Breast cancer highlights

Choosing Wisely in RT oncology

The REACT trial: Celecoxib vs placebo for primary breast cancer

Overall survival with abiraterone acetate plus prednisone in PEACE-1

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Microenvironment of tumours key to cancers progression

NCRI 2009: Non-FDG PET imaging

Magnetic nanotechnology to localise non-palpable breast cancers and concurrent sentinel node biopsy

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients

Time between melanoma excision and sentinel node biopsy does not affect survival

Stereotactic body radiotherapy compared with surgery for localised prostate cancer

Immunotherapy may slow the growth of malignant pleural mesothelioma

TargomiRs show promise in phase I study of malignant mesothelioma

CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC

Pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanoma